Work

Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Year: 2019

Type: article

Study design: Clinical Trial

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/j.clml.2019.07.220

Authors: Kerry A. Rogers, Philip A. Thompson, John N. Allan, Morton Coleman, Jeff P. Sharman, Bruce D. Cheson, Raquel Izumi, Melanie M. Frigault, Cheng Quah, Rakesh K. Raman, Min Hui Wang, Thomas J. Kipps

Institutions: The Ohio State University, The University of Texas MD Anderson Cancer Center, Weill Cornell Medicine, Willamette Valley Cancer Institute and Research Center, Georgetown University, Moores Cancer Center

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2970148977

FWCI: 0.136

Cites:

Cited by: 1

Related to: 10